Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$101.88 USD

101.88
9,197,343

-0.44 (-0.43%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $101.90 +0.02 (0.02%) 4:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Merck (MRK) Gets Priority Tag for Antiviral Drug Prevymis sNDA

The FDA grants priority review designation to Merck's (MRK) sNDA seeking expanded use of Prevymis. The PDUFA date is Jun 5, 2023.

Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?

Investors focus will likely be on Moderna's (MRNA) pipeline, especially with its late-stage pipeline candidates, when it reports fourth-quarter earnings.

Seagen's (SGEN) Q4 Earnings & Sales Beat Estimates, Stock Up

Seagen (SGEN) reports better-than-expected results in the fourth quarter of 2022, beating both earnings and sales estimates. Stock up in the after-market hours in response to the news.

The Zacks Analyst Blog Highlights Merck, Thermo Fisher Scientific, American Express, Valero Energy and Weyerhaeuser

Merck, Thermo Fisher Scientific, American Express, Valero Energy and Weyerhaeuser are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Merck, Thermo Fisher Scientific & American Express

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Thermo Fisher Scientific Inc. (TMO) and American Express Company (AXP).

AstraZeneca (AZN) Q4 Earnings Beat, Sales Hurt by COVID Jab

AstraZeneca (AZN) beats fourth-quarter estimates for earnings while missing the same for sales.

Sweta Killa headshot

A Look at Pharma ETFs Post Q4 Earnings

Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Derek Lewis headshot

AbbVie Q4 Preview: What's in Store?

AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc Lawsuits

Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.

Economic Data Deluge

Economic Data Deluge.

Merck (MRK) Beats on Q4 Earnings & Sales, 2023 View Disappoints

Merck (MRK) beats Q4 estimates for earnings and sales. Its 2023 profit guidance disappoints. Stock declines in pre-market.

Mark Vickery headshot

Goldilocks Econ Data Presides Over Pre-Market

We haven't thrown around the term "Goldilocks" too much lately, but this morning, the shoe fits.

Merck (MRK) Beats Q4 Earnings and Revenue Estimates

Merck (MRK) delivered earnings and revenue surprises of 3.85% and 0.65%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others

Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.

Will Keytruda & Gardasil Aid Merck (MRK) Sales in Q4 Earnings?

Merck's (MRK) key products like cancer drug Keytruda and HPV vaccine Gardasil are expected to have driven sales in Q4.

Why Merck & Co. (MRK) Might Surprise This Earnings Season

Merck & Co. (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Merck (MRK) to Report Q4 Earnings: What's in the Cards?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends

J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility.

Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?

Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar?

Style Box ETF report for PWV